Next Generation Antibody Therapeutics Market

SKU: DMPH1948 | Last Updated On: Nov 30 2021 | No. of Pages: 180 | Available Formats

> Global Next Generation Antibody Therapeutics Market is Expected to reach a high CAGR of 13% by 2028: DataM Intelligence

Global Next-Generation Antibody Therapeutics Market is segmented By Technology (Antibody-Drug Conjugates, Bispecific Antibodies, Biosimilar Antibody Products, Fc-engineered Antibodies, Antibody Fragments, and Antibody-Like Proteins, Others), By Therapeutic Area (Autoimmune/Inflammatory Next-Generation Antibody Therapeutics, Oncology Next-Generation Antibody Therapeutics), By End-User (Hospitals, Clinics, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2021-2028

 

Market Overview

The Global "Next Generation Antibody Therapeutics Market" is expected to grow at a high CAGR of 13% during the forecasting period (2021-2028).

Next-generation antibody therapeutics include using a new improvised therapeutic antibody to form innovative medicines for treating various diseases. Next-generation antibody therapeutics are developed clinically by pharmaceutical and biotechnology companies for several diseases.

Global Next Generation Antibody Therapeutics Market Value (USD Mn), 2018-2026

Market Dynamics

The global next-generation antibody therapeutics market is growing due to several factors such as the rising incidence of chronic diseases, the increasing emergence of antibody technology, new drug discovery, a large number of government initiatives, and growing research and development activities for new therapies. 
The rising prevalence of chronic diseases such as cancer, asthma, diabetes, and COPD boosts the growth of the next-generation antibody therapeutics market. For instance, according to National Cancer Institute, in 2018, in the United States, an estimated 1,735,350 new cancer cases will be diagnosed, and 609,640 people will die from the disease. The development of next-generation monoclonal antibodies has expanded beyond oncology into all therapeutic areas. For instance, ADCs were initially focused primarily on cancer. Still, Genentech has applied to infectious diseases, leading to THIOMAB antibiotic conjugates (TACs) to treat methicillin-resistant Staphylococcus aureus (MRSA).
The technological advancements in antibody therapeutics have led to the development of more efficient antibody therapeutics, hence, driving the growth in the next-generation antibody therapeutics market. Advanced technology in antibody therapeutics, such as antibody-drug conjugate (ADC) technology, glycoengineered antibody technology, and bispecific antibodies (BsAbs) technology, has resulted in the development of antibody therapeutics with improved characteristics. For instance, in August 2016, Catalent Pharma Solutions, a leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, and Zumutor Biologics Inc., a developer of biosimilars, novel bio betters, and New Biological Entities, completed a research study, combining Catalent’s proprietary GPEx® technology and Zumutor’s fucose knockout platform, to create new and more efficacious antibodies.
Antibody therapeutics are entering the clinical study and being approved increasingly. The commercial pipeline is robust with over 570 antibody therapeutics at various clinical phases, including 62 in late-stage clinical studies. Phase 1 to approval success rates are favorable, ranging from 17–25%, depending on the therapeutic area (cancer vs. non-cancer). In 2018, around 12 antibodies (such as erenumab (Aimovig), fremanezumab (Ajovy), galcanezumab (Emgality), burosumab (Crysvita), lanadelumab (Takhzyro), caplacizumab (Cablivi), mogamulizumab (Poteligeo), among others) that treat a wide variety of diseases were granted the first approval in either the European Union (EU) or United States (US). As of November 2018, 4 antibody therapeutics (sacituzumab govitecan, ravulizumab, risankizumab, romosozumab) were being considered for their first marketing approval in the EU or US, and an additional 3 antibody therapeutics developed by Chinese companies (tislelizumab, sintilimab, ocrelizumab) were in regulatory review in China. 
However, stringent government regulation, high cost, and time required for research and development activities hinder the growth of the global next-generation antibody therapeutics market.

Market Segmentation

Based on technology, the global next-generation antibody therapeutics market is segmented into Bispecific Antibodies (BsAbs), Biosimilar Antibody (Ab) Products, Antibody-Drug Conjugates (ADCs), Fc-engineered Antibodies, Antibody Fragments and Antibody-Like Proteins (AF & ALPs), and others. Among these, ADCs accounted for the largest market share in 2018 and are estimated to dominate during the forecast period. The advancement in ADC technology is one of the major trends in the next-generation antibody therapeutics market. The ADC technology combines the cytotoxic potential of chemotherapy and advantageous characteristics of antibodies, which leads to the high specificity and efficiency of ADCs. 
The ADC technology is majorly used for the manufacturing of next-generation antibody therapeutics for treating cancer. The ADCs are manufactured by linking an anti-cancer drug or another therapeutic agent to an antibody or antibody fragment. Because of the high efficiency delivered by ADCs, various pharmaceutical companies, such as Seattle Genetics Inc., ImmunoGen Inc., F. Hoffmann-La Roche Ltd, and Bristol-Myers Squibb Company, are actively involved in the development of next-generation antibody therapeutics using ADC technology.
The next-generation antibody therapeutics market can be segmented into oncology, autoimmune/inflammatory, and others based on therapeutic area. Among these, oncology accounted for the largest market share in 2018 due to rising cancer incidence globally. For instance, according to the World Health Organization (WHO), cancer accounts for 13% of deaths globally every year. Moreover, a 70% increase in cancer incidences is anticipated over the next couple of decades, and the global geriatric population is anticipated to nearly double from 12% to 22%, from 2015 to 2022. The incidence of all cancer types worldwide is anticipated to increase at a CAGR of 2.5% during 2015-2030. The mortality rate of cancers is likely to increase at a higher rate than the incidence rate during 2015-2030, at a CAGR of 2.6%. Sacituzumab govitecan, an antibody-drug conjugate (ADC) composed of a humanized anti-Trop-2 antibody conjugated to SN38, is studied to treat patients metastatic triple-negative breast cancer. Immunomedics, a pharmaceutical company focusing on developing antibody-drug conjugates for cancer treatment, plans clinical studies of the ADC in other cancers. Patients are being recruited for a pivotal Phase 2 study of sacituzumab govitecan to treat metastatic urothelial cancer.
Global Next Generation Antibody Therapeutics Market Share (%), By Technology, 2018

Market Geographical Analysis

North America holds the dominant market share for next-generation antibody therapeutics in 2018. It is expected to maintain the growth over the forecast period, owing to the increasing research & development activities, technological advancement in antibody therapies, rising healthcare expenditure and increasing government initiatives in this region. Besides, the rising incidence of chronic diseases and increasing approvals for new drugs also drive the market's growth. A total of 12 new antibodies were granted approvals in either the US or the EU during 2018. Perhaps reflecting the higher approval success rate for antibodies that are treatments for non-cancer indications, the majority (75%) of the products are for such diseases, including 3 for migraine prevention and 1 for human immunodeficiency virus (HIV) infection.
Asia-Pacific's next-generation antibody therapeutics market is growing at the highest CAGR during the forecast period (2020-2027) due to rising demand from developing countries such as India and China. The rising incidence of various diseases, increasing improvements in therapeutic antibodies, emerging antibody technologies, growing demand for better healthcare facilities and rapid growth in biosimilar antibodies and engineered antibodies are expected to offer new opportunities for the next-generation antibody therapeutics market in this region.

Global Next Generation Antibody Therapeutics Market Share (%), By Geography, 2018

Competitive Landscape

The Next Generation Antibody Therapeutics market is highly competitive with the presence of a large number of players. Some of the major players in the global Next-Generation Antibody Therapeutics market are Bayer AG, Amgen Inc., AstraZeneca PLC., Takeda Pharmaceuticals Company Limited, Pfizer Inc., Biogen, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, ImmunoGen Inc., Seattle Genetics Inc., among others.
The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations contributing to the Next Generation Antibody Therapeutics market's growth. Rising approval for new products is majorly contributing to the growth of the next-generation antibody therapeutics market globally. For instance, 
In June 2019, the U.S. FDA approved a new antibody-drug conjugate (ADC), Polivy (polatuzumab vedotin-piiq), to treat adult patients with diffuse large B-cell lymphoma (DLBCL).
On September 27, 2018, the FDA approved galcanezumab-gnlm (Emgality®) for the preventive treatment of migraine in adults, making Emgality the third antibody therapeutic approved by FDA in 2018 for this indication.
On September 14, 2018, the FDA approved fremanezumab-vfrm (AjovyTM) for the preventive treatment of migraines in adults.
On August 23, 2018, the FDA approved a lanadelumab-flyo (TakhzyroTM) injection for prophylaxis to prevent hereditary angioedema (HAE) attacks in patients 12 years of age and older.
On May 17, 2018, the US Food and Drug Administration (FDA) approved erenumab-aooe (Aimovig) for the preventive treatment of migraines in adults.

Why Purchase the Report?

•    Visualize the composition of the next-generation antibody therapeutics market by technology and end-user, highlighting the key commercial assets and players.

•    Identify commercial opportunities in the next-generation antibody therapeutics market by analyzing trends and co-development deals. 

•    Excel data sheet with thousands of data points of next-generation antibody therapeutics market-level 4/5 segmentation.

•    PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

•    Product mapping in excel for the key product of all major market players

Target Audience

•    Service Providers/ Buyers
•    Industry Investors/Investment Bankers
•    Education & Research Institutes
•    Research Professionals
•    Emerging Companies
•    Manufacturers

Trending Topics

Monoclonal Antibody Therapeutics Market

Antibody Drug Conjugates

 

 

Table of Contents

  1. Global Next-Generation Antibody Therapeutics Market Methodology and Scope

    1. Research Methodology
    2. Research Objective and Scope of the Report
  2. Global Next Generation Antibody Therapeutics Market – Market Definition and Overview

  3. Global Next Generation Antibody Therapeutics Market – Executive Summary

    1. Market Snippet by Technology
    2. Market Snippet by Therapeutic Area
    3. Market Snippet by End-User
  4. Global Next Generation Antibody Therapeutics Market Dynamics

    1. Market Impacting Factors
      1. Drivers
        1. Increasing prevalence of chronic diseases
        2. Technological progressions in antibody therapeutics
      2. Restraints
        1. High cost of next-generation antibody therapeutics
        2. Stringent Regulations
      3. Opportunity
      4. Impact Analysis
  5. Global Next Generation Antibody Therapeutics Market – Industry Analysis

    1. Porter's Five Forces Analysis
    2. Regulatory Analysis
    3. Supply Chain Analysis
    4. Pricing Analysis
    5. Pipeline Drugs Analysis
    6. Unmet Needs
  6. Global Next Generation Antibody Therapeutics Market – By Technology

    1. Introduction
    2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology Segment
    3. Market Attractiveness Index, By Technology Segment
        1. Antibody-Drug Conjugates (ADCs)*
        2. Introduction
        3. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2028
        4. Bispecific Antibodies (BsAbs)
        5. Biosimilar Antibody (Ab) Products
        6. Fc-engineered Antibodies
        7. Antibody Fragments and Antibody-Like Proteins (AF & ALPs)
        8. Others
  7. Global Next Generation Antibody Therapeutics Market – By Therapeutic Area

    1. Introduction
    2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutic Area Segment
    3. Market Attractiveness Index, By Therapeutic Area Segment
      1. Autoimmune/Inflammatory Next-Generation Antibody Therapeutics*
        1. Introduction
        2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2028
      2. Oncology Next-Generation Antibody Therapeutics
  8. Global Next Generation Antibody Therapeutics Market – By End-User

    1. Introduction
    2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User Segment
    3. Market Attractiveness Index, By End-User Segment
      1. Hospitals*
        1. Introduction
        2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2028
      2. Clinics
      3. Others
  9. Global Next Generation Antibody Therapeutics Market – By Region

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
      2. Market Attractiveness Index, By Region
    2. North America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutic Area
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. The U.S.
        2. Canada
        3. Mexico
    3. Europe
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutic Area
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Germany
        2. The U.K.
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
    4. South America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutic Area
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Brazil
        2. Argentina
        3. Rest of South America
    5. Asia Pacific
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutic Area
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. China
        2. India
        3. Japan
        4. Australia
        5. Rest of Asia Pacific
    6. The Middle East and Africa
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutic Area
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  10. Global Next Generation Antibody Therapeutics Market – Competitive Landscape

    1. Competitive Scenario
    2. Market Positioning/Share Analysis
    3. Mergers and Acquisitions Analysis
  11. Company Profiles
    1. Amgen Inc.*
      1. Company Overview
      2. Product Portfolio and Description
      3. Key Highlights
      4. Financial Overview
    2. Bayer AG
    3. AstraZeneca PLC.
    4. Takeda Pharmaceuticals Company Limited
    5. Pfizer Inc.
    6. Biogen
    7. F. Hoffmann-La Roche Ltd
    8. Bristol-Myers Squibb Company
    9. ImmunoGen Inc.
    10. Seattle Genetics Inc.
  12. Global Next Generation Antibody Therapeutics Market – Premium Insights

  13. Global Next Generation Antibody Therapeutics Market – DataM

    1. Appendix
    2. About Us and Services
    3. Contact Us

List of Tables & Figures

List of Tables

Table 1 Global Next Generation Antibody Therapeutics Market Value, By Technology, 2018,2022 & 2028 ($ Million)
Table 2 Global Next Generation Antibody Therapeutics Market Value, By Therapeutic Area, 2018,2022 & 2028 ($ Million)
Table 3 Global Next Generation Antibody Therapeutics Market Value, By End-User, 2018,2022 & 2028 ($ Million)
Table 4 Global Next Generation Antibody Therapeutics Market Value, By Region, 2018,2022 & 2028 ($ Million)
Table 5 Global Next Generation Antibody Therapeutics Market Value, By Technology, 2018,2022 & 2028 ($ Million)
Table 6 Global Next Generation Antibody Therapeutics Market Value, By Technology, 2017-2028 ($ Million)
Table 7 Global Next Generation Antibody Therapeutics Market Value, By Therapeutic Area, 2018,2022 & 2028 ($ Million)
Table 8 Global Next Generation Antibody Therapeutics Market Value, By Therapeutic Area, 2017-2028 ($ Million)
Table 9 Global Next Generation Antibody Therapeutics Market Value, By End-User, 2018,2022 & 2028 ($ Million)
Table 10 Global Next Generation Antibody Therapeutics Market Value, By End-User, 2017-2028 ($ Million)
Table 11 Global Next Generation Antibody Therapeutics Market Value, By Region, 2018,2022 & 2028 ($ Million)
Table 12 Global Next Generation Antibody Therapeutics Market Value, By Region, 2017-2028 ($ Million)
Table 13 North America Next Generation Antibody Therapeutics Market Value, By Technology, 2017-2028 ($ Million)
Table 14 North America Next Generation Antibody Therapeutics Market Value, By Therapeutic Area, 2017-2028 ($ Million)
Table 15 North America Next Generation Antibody Therapeutics Market Value, By End-User, 2017-2028 ($ Million)
Table 16 North America Next Generation Antibody Therapeutics Market Value, By Country, 2017-2028 ($ Million)
Table 17 South America Next Generation Antibody Therapeutics Market Value, By Technology, 2017-2028 ($ Million)
Table 18 South America Next Generation Antibody Therapeutics Market Value, By Therapeutic Area, 2017-2028 ($ Million)
Table 19 South America Next Generation Antibody Therapeutics Market Value, By End-User, 2017-2028 ($ Million)
Table 20 South America Next Generation Antibody Therapeutics Market Value, By Country, 2017-2028 ($ Million)
Table 21 Europe Next Generation Antibody Therapeutics Market Value, By Technology, 2017-2028 ($ Million)
Table 22 Europe Next Generation Antibody Therapeutics Market Value, By Therapeutic Area, 2017-2028 ($ Million)
Table 23 Europe Next Generation Antibody Therapeutics Market Value, By End-User, 2017-2028 ($ Million)
Table 24 Europe Next Generation Antibody Therapeutics Market Value, By Country, 2017-2028 ($ Million)
Table 25 Asia-Pacific Next Generation Antibody Therapeutics Market Value, By Technology, 2017-2028 ($ Million)
Table 26 Asia-Pacific Next Generation Antibody Therapeutics Market Value, By Therapeutic Area, 2017-2028 ($ Million)
Table 27 Asia-Pacific Next Generation Antibody Therapeutics Market Value, By End-User, 2017-2028 ($ Million)
Table 28 Asia-Pacific Next Generation Antibody Therapeutics Market Value, By Country, 2017-2028 ($ Million)
Table 29 Middle East & Africa Next Generation Antibody Therapeutics Market Value, By Technology, 2017-2028 ($ Million)
Table 30 Middle East & Africa Next Generation Antibody Therapeutics Market Value, By Therapeutic Area, 2017-2028 ($ Million)
Table 31 Middle East & Africa Next Generation Antibody Therapeutics Market Value, By End-User, 2017-2028 ($ Million)
Table 32 Bayer AG: Overview
Table 33 Bayer AG: Product Portfolio
Table 34 Bayer AG: Key Developments
Table 35 Amgen Inc.: Overview
Table 36 Amgen Inc.: Product Portfolio
Table 37 Amgen Inc.: Key Developments
Table 38 AstraZeneca PLC.: Overview
Table 39 AstraZeneca PLC.: Product Portfolio
Table 40 AstraZeneca PLC.: Key Developments
Table 41 Takeda Pharmaceuticals Company Limited: Overview
Table 42 Takeda Pharmaceuticals Company Limited: Product Portfolio
Table 43 Takeda Pharmaceuticals Company Limited: Key Developments
Table 44 Pfizer Inc.: Overview
Table 45 Pfizer Inc.: Product Portfolio
Table 46 Pfizer Inc.: Key Developments
Table 47 Biogen: Overview
Table 48 Biogen: Product Portfolio
Table 49 Biogen: Key Developments
Table 50 F. Hoffmann-La Roche Ltd: Overview
Table 51 F. Hoffmann-La Roche Ltd: Product Portfolio
Table 52 F. Hoffmann-La Roche Ltd: Key Developments
Table 53 Bristol-Myers Squibb Company: Overview
Table 54 Bristol-Myers Squibb Company: Product Portfolio
Table 55 Bristol-Myers Squibb Company: Key Developments
Table 56 ImmunoGen Inc.: Overview
Table 57 ImmunoGen Inc.: Product Portfolio
Table 58 ImmunoGen Inc.: Key Developments
Table 59 Seattle Genetics Inc.: Overview
Table 60 Seattle Genetics Inc.: Product Portfolio
Table 61 Seattle Genetics Inc.: Key Developments

 List of Figures

Figure 1 Global Next Generation Antibody Therapeutics Market Share, By Technology, 2018 & 2028 (%)
Figure 2 Global Next Generation Antibody Therapeutics Market Share, By Therapeutic Area, 2018 & 2028 (%)
Figure 3 Global Next Generation Antibody Therapeutics Market Share, By End-User, 2018 & 2028 (%)
Figure 4 Global Next Generation Antibody Therapeutics Market Share, By Region, 2018 & 2028 (%)
Figure 5 Global Next Generation Antibody Therapeutics Market Value, 2017-2028 ($ Million)
Figure 6 Global Next Generation Antibody Therapeutics Market Y-o-Y Growth, By Technology, 2018-2028 (%)
Figure 7 Bispecific Antibodies (BsAbs): Global Next Generation Antibody Therapeutics Market Value, 2017-2028 ($ Million)
Figure 8 Biosimilar Antibody (Ab) Products: Global Next Generation Antibody Therapeutics Market Value, 2017-2028 ($ Million)
Figure 9 Antibody-Drug Conjugates (ADCs): Global Next Generation Antibody Therapeutics Market Value, 2017-2028 ($ Million)
Figure 10 Fc-engineered Antibodies: Global Next Generation Antibody Therapeutics Market Value, 2017-2028 ($ Million)
Figure 11 Antibody Fragments and Antibody-Like Proteins (AF & ALPs): Global Next Generation Antibody Therapeutics Market Value, 2017-2028 ($ Million)
Figure 12 Others: Global Next Generation Antibody Therapeutics Market Value, 2017-2028 ($ Million)
Figure 13 Global Next Generation Antibody Therapeutics Market Y-o-Y Growth, By Therapeutic Area, 2018-2028 (%)
Figure 14 Autoimmune/Inflammatory: Global Next Generation Antibody Therapeutics Market Value, 2017-2028 ($ Million)
Figure 15 Oncology: Global Next Generation Antibody Therapeutics Market Value, 2017-2028 ($ Million)
Figure 16 Others: Global Next Generation Antibody Therapeutics Market Value, 2017-2028 ($ Million)
Figure 17 Global Next Generation Antibody Therapeutics Market Y-o-Y Growth, By End-User, 2018-2028 (%)
Figure 18 Hospitals: Global Next Generation Antibody Therapeutics Market Value, 2017-2028 ($ Million)
Figure 19 Clinics: Global Next Generation Antibody Therapeutics Market Value, 2017-2028 ($ Million)
Figure 20 Others: Global Next Generation Antibody Therapeutics Market Value, 2017-2028 ($ Million)
Figure 21 Global Next Generation Antibody Therapeutics Market Y-o-Y Growth, By Region, 2018-2028 (%)
Figure 22 North America Next Generation Antibody Therapeutics Market Value, 2017-2028 ($ Million)
Figure 23 North America Next Generation Antibody Therapeutics Market Share, By Technology, 2018 & 2028 (%)
Figure 24 North America Next Generation Antibody Therapeutics Market Share, By Therapeutic Area, 2018 & 2028 (%)
Figure 25 North America Next Generation Antibody Therapeutics Market Share, By End-User, 2018 & 2028 (%)
Figure 26 North America Next Generation Antibody Therapeutics Market Share, By Country, 2018 & 2028 (%)
Figure 27 South America Next Generation Antibody Therapeutics Market Value, 2017-2028 ($ Million)
Figure 28 South America Next Generation Antibody Therapeutics Market Share, By Technology, 2018 & 2028 (%)
Figure 29 South America Next Generation Antibody Therapeutics Market Share, By Therapeutic Area, 2018 & 2028 (%)
Figure 30 South America Next Generation Antibody Therapeutics Market Share, By End-User, 2018 & 2028 (%)
Figure 31 South America Next Generation Antibody Therapeutics Market Share, By Country, 2018 & 2028 (%)
Figure 32 Europe Next Generation Antibody Therapeutics Market Value, 2017-2028 ($ Million)
Figure 33 Europe Next Generation Antibody Therapeutics Market Share, By Technology, 2018 & 2028 (%)
Figure 34 Europe Next Generation Antibody Therapeutics Market Share, By Therapeutic Area, 2018 & 2028 (%)
Figure 35 Europe Next Generation Antibody Therapeutics Market Share, By End-User, 2018 & 2028 (%)
Figure 36 Europe Next Generation Antibody Therapeutics Market Share, By Country, 2018 & 2028 (%)
Figure 37 Asia-Pacific Next Generation Antibody Therapeutics Market Value, 2017-2028 ($ Million)
Figure 38 Asia-Pacific Next Generation Antibody Therapeutics Market Share, By Technology, 2018 & 2028 (%)
Figure 39 Asia-Pacific Next Generation Antibody Therapeutics Market Share, By Therapeutic Area, 2018 & 2028 (%)
Figure 40 Asia-Pacific Next Generation Antibody Therapeutics Market Share, By End-User, 2018 & 2028 (%)
Figure 41 Asia-Pacific Next Generation Antibody Therapeutics Market Share, By Country, 2018 & 2028 (%)
Figure 42 Middle East & Africa Next Generation Antibody Therapeutics Market Value, 2017-2028 ($ Million)
Figure 43 Middle East & Africa Next Generation Antibody Therapeutics Market Share, By Technology, 2018 & 2028 (%)
Figure 44 Middle East & Africa Next Generation Antibody Therapeutics Market Share, By Therapeutic Area, 2018 & 2028 (%)
Figure 45 Middle East & Africa Next Generation Antibody Therapeutics Market Share, By End-User, 2018 & 2028 (%)
Figure 46 Bayer AG: Financials
Figure 47 Amgen Inc.: Financials
Figure 48 AstraZeneca PLC.: Financials
Figure 49 Takeda Pharmaceuticals Company Limited: Financials
Figure 50 Pfizer Inc.: Financials
Figure 51 Biogen: Financials
Figure 52 F. Hoffmann-La Roche Ltd: Financials
Figure 53 Bristol-Myers Squibb Company: Financials
Figure 54 ImmunoGen Inc.: Financials
Figure 55 Seattle Genetics Inc.: Financials

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*



Year-End Offer from
DataM Intelligence

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest